An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
The RCT evidence showed clinical benefits from everolimus and sunitinib in neuroendocrine tumours, while the cost-effectiveness of the drugs ranged from about £20,000 to nearly £200,000 per QALY.
1 Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK
2 Plymouth Oncology Centre, Plymouth Hospitals NHS Trust, Plymouth, UK
3 Exeter Oncology Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK
4 Neuroendocrine Tumour Service, King’s College Hospital NHS Foundation Trust, London, UK
* Corresponding author Email: R.E.Mujica-Mota@exeter.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document